Cargando…

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease

INTRODUCTION: The progression rate of Alzheimer's disease (AD) varies and might be affected by the triggering receptor expressed on myeloid cells (TREM2) activity. We explored if cerebrospinal fluid (CSF) soluble TREM2 (sTREM2), a proxy of microglial activity, is associated with clinical progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwin, Trine Holt, Henjum, Kristi, Nilsson, Lars N.G., Watne, Leiv Otto, Persson, Karin, Eldholm, Rannveig Sakshaug, Saltvedt, Ingvild, Halaas, Nathalie Bodd, Selbæk, Geir, Engedal, Knut, Strand, Bjørn Heine, Knapskog, Anne‐Brita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cerebrospinal Fluid Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720866/ https://www.ncbi.nlm.nih.gov/pubmed/33313376 http://dx.doi.org/10.1002/dad2.12128

Ejemplares similares

Cerebrospinal fluid sTREM2 in Alzheimer’s disease: comparisons between clinical presentation and AT classification
por: Knapskog, Anne-Brita, et al.
Publicado: (2020)

Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
por: Henjum, Kristi, et al.
Publicado: (2022)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease‐Opportunities for Therapy
por: Carare, Roxana O., et al.
Publicado: (2020)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys
por: Boehnke, Susan E., et al.
Publicado: (2020)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
por: DeMarco, Mari L., et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

Deciphering the factors that influence participation in studies requiring serial lumbar punctures
por: Day, Gregory S., et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

Association of cognitive impairment severity with potentially avoidable readmissions: A retrospective cohort study of 8897 older patients
por: Mitsutake, Seigo, et al.
Publicado: (2021)

Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
por: Skillbäck, Tobias, et al.
Publicado: (2021)

Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study
por: Clark, Alexandra L., et al.
Publicado: (2021)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Diagnostic and prognostic performance of CSF α‐synuclein in prion disease in the context of rapidly progressive dementia
por: Mastrangelo, Andrea, et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta status
por: Morar, Ulyana, et al.
Publicado: (2022)

Association between vascular comorbidity and progression of Alzheimer’s disease: a two-year observational study in Norwegian memory clinics
por: Eldholm, Rannveig Sakshaug, et al.
Publicado: (2018)

Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients
por: Knapskog, Anne-Brita, et al.
Publicado: (2017)

Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991)

Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease
por: Aksnes, Mari, et al.
Publicado: (2023)

MRI-assessed atrophy subtypes in Alzheimer’s disease and the cognitive reserve hypothesis
por: Persson, Karin, et al.
Publicado: (2017)

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume
por: Sapkota, Shraddha, et al.
Publicado: (2022)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Brain Morphometric Correlates of Depressive Symptoms among Patients with and without Dementia
por: Barca, Maria Lage, et al.
Publicado: (2022)

A proposed role for efflux transporters in the pathogenesis of hydrocephalus
por: Krishnamurthy, Satish, et al.
Publicado: (2014)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uku27u7flj4mosp7g2190v83c3